CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey

The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal HER2 negative metastatic breast cancer. Their effectiveness is confirmed not only by randomized, but also observational studies on a wide heter...

Full description

Bibliographic Details
Main Authors: E. V. Artamonova, E. I. Kovalenko, L. V. Bolotina, M. B. Stenina, R. V. Orlova, M. A. Mukhina
Format: Article
Language:Russian
Published: ABV-press 2021-01-01
Series:Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:
metastatic breast cancer
cdk4/6 inhibitors
palbociclib
russian clinical practice
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/765

Internet

https://ojrs.abvpress.ru/ojrs/article/view/765

Similar Items